Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy Enrolling in US, Europe

Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy Enrolling in US, Europe

291680

Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy Enrolling in US, Europe

A Phase 3 trial investigating GA Depot, a long-acting, once-a-month injectable formulation of glatiramer acetate, is seeking patients with relapsing forms of multiple sclerosis (MS). The global study (NCT04121221) aims to include 960 adults, ages 18 to 55, diagnosed with clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). Enrollment opened in 2019, with clinical sites in the U.S. and Eastern Europe added since then. More information on contacts and locations can be found here. People in…

You must be logged in to read/download the full post.